Qidni Labs Inc. develops portable dialysis machines and cartridge-based blood purification technology for selective removal of uremic toxins and other solutes from whole blood. Its Qidni/D and Qartridge technologies are intended for dialysis in home, rural, emergency, military, satellite-clinic, pandemic, and other resource-limited settings, but the company states the devices are not approved for commercial sale.
NRC Industrial Research Assistance Program (NRC-IRAP)
Compliance program
Novel Microdevices, IncBaltimore-based Novel Microdevices develops portable, sample-to-answer molecular diagnostic systems built around disposable microfluidic cartridges. Its battery-powered Novel Dx platform is designed to deliver lab-quality PCR results in about 15 minutes, including testing for respiratory infections and other diseases at the point of care. The company is establishing a GMP-compliant pilot manufacturing facility at its Baltimore headquarters to scale cartridge production.BALTIMORE, MD
BioMedical Enterprises, IncFounded by nephrologist Alfredo Zarate, MD, BioMedical Enterprises develops medical devices aimed at difficult clinical problems, including bloodstream infections, temperature management and cancer screening. Its earlier work on hemodialysis produced a patented needle designed to reduce blood-cell damage and inflammatory-factor release, earning support from the National Institutes of Health’s commercialization program. The company’s newer devices are built around identified unmet needs and are being prepared for validation and commercialization.BETHESDA, MD
Chloros Medical LLCChloros Medical LLC is developing technology for disinfecting ultrasound probes. Its technology is in development and is not yet FDA cleared for use.
Laminate Medical Technologies LtdFounded in 2012 by engineer Tammy Gilon and Dr. Eyal Orion, Laminate Medical Technologies develops medical devices aimed at making arteriovenous fistulas more usable for people receiving hemodialysis. Its flagship VasQ extravascular support device reinforces the fistula’s connection during maturation and is sold across the United States, Europe, Africa, Singapore and the United Kingdom. The company’s team spans Israel, Europe and the United States, with VasQ supported by CE marking and FDA clinical development.NEW YORK, NY.png/:/rs=h:75,cg:true,m/qt=q:100/ll)